CDC/ACIP [to 14 Dec 2019]

CDC/ACIP [to 14 Dec 2019]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html

MMWR News Synopsis for Friday, December 13, 2019
Recommendations and Reports:
Use of Anthrax Vaccine in the United States Recommendations of the Advisory Committee on Immunization Practices, 2019
Today’s report summarizes safety and estimated efficacy data and updates 2009 recommendations from the CDC Advisory Committee on Immunization Practices (ACIP) regarding use of anthrax vaccine in the United States. The report also includes several changes from previous guidance that might be used to guide bioterrorism preparedness planning efforts. These updated recommendations increase the capacity and ease of use of the vaccine in an event where large scale vaccination might be needed.
Today’s report summarizes vaccine safety and estimated efficacy data, and updates CDC Advisory Committee on Immunization Practices (ACIP) recommendations regarding use of anthrax vaccine in the United States. Changes from previous guidance include: 1) extending the booster dose interval for pre-exposure vaccination from 1 to 3 years for people who are not at high risk for exposure to anthrax; 2) recommending intramuscular vaccine administration during an emergency response if the subcutaneous route poses significant challenges; 3) recommendations on dose-sparing vaccine regimens; and 4) clarification on how long antimicrobial therapy is needed when used with vaccine for post-exposure prophylaxis. These updated recommendations can be used to guide preparedness planning for a widespread release of B. anthracis spores, and increase capacity and ease of use of the vaccine in an event where large scale vaccination is needed.